155 related articles for article (PubMed ID: 38123199)
41. [Expression of METTL14 in epithelial ovarian cancer and the effect on cell proliferation, invasion and migration of A2780 and SKOV3 cells].
Wei YS; Yao DS; Li L; Lu Y; Yang XM; Zhang WG
Zhonghua Fu Chan Ke Za Zhi; 2022 Jan; 57(1):46-56. PubMed ID: 35090245
[No Abstract] [Full Text] [Related]
42. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
[TBL] [Abstract][Full Text] [Related]
43. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
[TBL] [Abstract][Full Text] [Related]
44. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
45. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma.
Zhong L; Liu X; Wang L; Liu Y; Zhang D; Zhao Y
J Ovarian Res; 2022 Jan; 15(1):7. PubMed ID: 35027053
[TBL] [Abstract][Full Text] [Related]
47. [IL-1β inhibitor sensitizes to olaparib in homologous recombination deficiency proficient ovarian cancer cells].
Xu JF; Cen YX; Tang SS; Ren Y; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2022 Jul; 57(7):519-529. PubMed ID: 35902786
[No Abstract] [Full Text] [Related]
48. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
49. The Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 Promotes Ovarian Cancer Pathogenesis.
Hillemeyer L; Espinoza-Sanchez NA; Greve B; Hassan N; Chelariu-Raicu A; Kiesel L; Götte M
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628603
[TBL] [Abstract][Full Text] [Related]
50. [Suppression of WWOX gene by RNA interference reverses platinum resistance acquired in SKOV3/SB cells].
Liu YY; Li L; Li DR; Zhang W; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):854-8. PubMed ID: 19087571
[TBL] [Abstract][Full Text] [Related]
51. BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells.
Laatio L; Myllynen P; Serpi R; Rysä J; Ilves M; Lappi-Blanco E; Ruskoaho H; Vähäkangas K; Puistola U
Tumour Biol; 2011 Oct; 32(5):985-95. PubMed ID: 21674241
[TBL] [Abstract][Full Text] [Related]
52. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
[TBL] [Abstract][Full Text] [Related]
53. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
54. Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.
Park SH; Song JY; Kim YK; Heo JH; Kang H; Kim G; An HJ; Kim TH
Int J Oncol; 2014 Mar; 44(3):637-46. PubMed ID: 24378809
[TBL] [Abstract][Full Text] [Related]
55. [Effect and mechanism of endoplasmic reticulum stress on cisplatin resistance in ovarian carcinoma].
Tian J; Hu X; Qu Q
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):324-8. PubMed ID: 25030585
[TBL] [Abstract][Full Text] [Related]
56. [Effect of circBIRC6 targeting miR-367-3p on cisplatin resistance of ovarian cancer cells].
Zhang J; Bai HJ
Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1062-1068. PubMed ID: 34695896
[No Abstract] [Full Text] [Related]
57. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
58. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
[TBL] [Abstract][Full Text] [Related]
59. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
Shi L; Yu H; Zhang W; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
[TBL] [Abstract][Full Text] [Related]
60. The clinical significance and biological function of lncRNA SOCAR in serous ovarian carcinoma.
Guo Q; Wang L; Zhu L; Lu X; Song Y; Sun J; Wu Z; Shi J; Wang Z; Zhou X
Gene; 2019 Sep; 713():143969. PubMed ID: 31299360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
